Welcome!

News Feed Item

Milestone Scientific Reports Fourth Quarter and 2013 Financial Results

Revenue Increases 15.8% to $10.0 Million in 2013; Domestic Instrument Sales Increase 44.8%; Achieves Net Income of $1.5 Million in 2013; Shareholders' Equity Increases to $5.5 Million at the End of Fiscal 2013 Compared to $1.9 Million at the End

LIVINGSTON, NJ--(Marketwired - March 12, 2014) - Milestone Scientific Inc. (OTCQB: MLSS), a leading medical research and development company that designs and patents innovative injection technology, today announced financial results for the fourth quarter and year ended December 31, 2013.

2013 Operating Highlights:

  • Formed a strategic partnership with Tri-anim Health Services Inc., a division of Sarnova Inc., one of the nation's largest specialty distributors of healthcare products, to distribute Milestone Medical's epidural instrument
  • Listed Milestone Medical subsidiary on the Warsaw Stock Exchange and raised $3 million from European investors
  • Implemented the use of the Wand® STA instrument in additional college and university dental hygienist programs

Leonard Osser, Chief Executive Officer of Milestone Scientific stated, "We are pleased to report positive financial results for the year ended December 31, 2013. We continue to see top and bottom line growth, with revenue increasing 15.8% to $10.0 million and net income increasing to $1.5 million for 2013, compared to a net loss of approximately ($870,306) in 2012. Notably, we achieved a 44.8% increase in domestic instrument sales to $1.2 million in 2013. At the same time, our balance sheet continues to improve as we increased shareholders' equity to $5.5 million as of December 31, 2013. The improvement in shareholders' equity was principally attributable to the increase in net income, conversion of a long term note, and a small private placement in 2013."

"We continue to maintain a successful distribution relationship with Aseptico, which provides us greater transparency with our customers. As a result, we are able to establish a direct relationship with dentists and provide them with a training program through our in-house education staff as well as our hygienists in the field to make an effort to have them use the instrument to the fullest capacity. Due to certain sales incentives and arrangements with our distributors, we anticipate lower handpiece sales in the first quarter and second quarter of 2014 as compared to the fourth quarter of 2013. However, we expect to more than make up for this decline in the second half of 2014 since we know from experience that once we train dentists, they utilize a greater number of handpieces each year. We are also implementing promotions and incentives on the Wand® STA instruments in 2014 to our distributors worldwide which should increase instrument sales. The increase in instrument sales will help drive handpiece sales beginning in the second half of 2014, which will result in increased sales and increased bottom line but lower margins.

"In 2013, we announced a strategic partnership with Tri-anim Health Services Inc., one of the nation's largest specialty distributors of healthcare products. Upon FDA approval, Tri-anim will be the exclusive distributer of Milestone Medical's epidural instrument. Tri-anim is one of the largest distributors to birthing hospitals across the U.S., and is an important validation of the market potential for our instruments."

"Lastly, our subsidiary, Milestone Medical Inc., recently listed on the Warsaw Stock Exchange. The listing followed a $3 million raise from European investors. The money we raised in Poland will help us accelerate the launch of our first two medical instruments, epidural and intra-articular, which are based on our patented Dynamic Pressure Sensing® system. We believe these first two medical instruments represent a significant market opportunity for both Milestone Medical Inc. and Milestone Scientific Inc. We look forward to introducing additional instruments serving a wide array of medical applications, and believe this recent funding demonstrates our ability to cost-effectively bring new instruments to market, while minimizing dilution to shareholders."

Revenue for the three months ended December 31, 2013 increased 23.3% to $2.8 million versus $2.3 million for the fourth quarter of 2012. Domestic instrument sales increased by 30.9% to $378,801 in the fourth quarter of 2013 versus the same quarter in 2012 due to the increased demand at the distributor and group dental practice levels. In the domestic market, handpiece sales increased by $211,547 or 27.3%. On the international front, total revenue was $1,407,455, a 18.9% increase versus the same period in 2012. International handpiece sales increased by $166,973 or 20.6% in the fourth quarter of 2013 versus 2012. Gross profit for the fourth quarter of 2013 was $1.8 million or 65.5% of revenue versus $1.4 million or 59.8% of revenue in the fourth quarter of 2012. Net income for the fourth quarter of 2013 was $1.0 million, or $0.05 per diluted share, versus net loss of ($365,735), or ($0.02) per diluted share for the comparable period in 2012. 

Revenue for the year ended December 31, 2013 increased 15.8% to $10.0 million versus $8.6 million for the year ended 2012. The increase in product sales of $1,363,178 was primarily the result of increased domestic revenue. Domestic instrument sales increased by $377,752 or 44.8% in 2013 versus 2012 due to increased demand at the distributor and group dental practice levels. In the domestic market, handpiece sales increased by $561,355 or 16.5%. International instrument sales increased by $147,517 or 11.3% in 2013 versus 2012. In the international market, handpiece sales increased by $389,434 or 13.2%. Gross profit for 2013 was $6.8 million or 68.0% of revenue versus $5.6 million or 64.7% of revenue in 2012. Operating income for 2013 was $1.1 million versus operating loss of ($520,353) for 2012. Net income for 2013 was $1.5 million or $0.08 per diluted share, versus net loss of ($870,306), or ($0.05) per diluted share in 2012. The increase in net income is attributable to an increase in sales and gross margin dollars, as well as a significant decrease in selling, general and administrative expenses and the net positive impact of Milestone Medical Inc. (joint venture). 

Milestone's executive management team will host a teleconference on Thursday, March 13th at 8:30am Eastern Daylight Time to discuss the company's financial results. The conference call can be accessed via telephone by dialing toll free 1-877-941-9205. For those unable to participate at that time, a replay of the call can be accessed by dialing 1-800-406-7325 and entering the pass code 4673676. The replay will be available for 90 days.

About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com

Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2013. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

                                                                            
                                                                            
                         MILESTONE SCIENTIFIC INC.                          
                     CONDENSED STATEMENTS OF OPERATIONS                     
                                (Unaudited)                                 
                                                                            
                                                                            
                                                                            
                                             December 31,     December 31,  
                                                 2013             2012      
                                           ---------------  --------------- 
Product sales, net                         $    10,011,420  $     8,648,242 
Cost of products sold                            3,198,908        3,055,991 
                                           ---------------  --------------- 
Gross profit                                     6,812,512        5,592,251 
                                           ---------------  --------------- 
Selling, general and administrative                                         
 expenses                                        5,534,463        5,930,625 
Research and development expenses                  191,345          181,979 
                                           ---------------  --------------- 
  Total operating expenses                       5,725,808        6,112,604 
                                           ---------------  --------------- 
    Income (loss) from operations                1,086,704         (520,353)
Other income (expense)                                                      
  Other income                                      17,543                - 
  Interest income                                      115               34 
  Interest expense                                 (70,801)        (175,905)
  Interest-Amortized debt issuance - cost                -           (3,065)
  Loss on Earnings from Medical Joint                                       
   Venture                                        (924,363)        (171,016)
  Loss on Earnings from Education Joint                                     
   Venture                                          (7,918)               - 
  Gain on dilutive effect on Medical Joint                                  
   Venture stock issuance                        1,363,650                - 
                                           ---------------  --------------- 
    Total other expense, net                       378,226         (349,952)
                                           ---------------  --------------- 
      Income (loss)                              1,464,930         (870,306)
                                           ---------------  --------------- 
Provision for Income Tax                                 -                - 
                                           ---------------  --------------- 
      Net income (loss)                    $     1,464,930  $      (870,306)
                                           ===============  =============== 
Net income (loss) per share applicable to                                   
 common stockholders -                                                      
  Basic                                    $          0.09  $         (0.05)
                                           ===============  =============== 
  Diluted                                  $          0.08  $         (0.05)
                                           ===============  =============== 
Weighted average shares outstanding and to                                  
 be issued -                                                                
  Basic                                         17,127,468       16,080,474 
                                           ===============  =============== 
  Diluted                                       17,483,638       16,080,474 
                                           ===============  =============== 
                                                                            
                                                                            
                                                                            
                          MILESTONE SCIENTIFIC INC.                         
                          CONDENSED BALANCE SHEETS                          
                                                                            
                                                                            
                                                                            
                                       December 31, 2013  December 31, 2012 
                                       -----------------  ----------------- 
                                                                            
                ASSETS                                                      
Current Assets:                                                             
  Cash and cash equivalents            $       1,147,198  $         165,249 
  Accounts receivable, net of                                               
   allowance for doubtful accounts of                                       
   $5,000 in 2013 and $179,259 in 2012         1,532,856            978,982 
  Inventories                                  1,321,652            638,561 
  Advances on contracts                          727,478            476,969 
  Prepaid expenses and other current                                        
   assets                                        150,451            239,061 
                                       -----------------  ----------------- 
    Total current assets                       4,879,635          2,498,822 
Accounts receivable-long term, net of                                       
 allowance for doubtful accounts                                            
of $167,971 in 2012                                    -            119,201 
Advances on contracts                          1,580,874          2,350,477 
Investment in Milestone Medical Inc              924,115                  - 
Investment in Milestone Education LLC             42,082                  - 
Furniture, Fixtures & Equipment net of                                      
 accumulated depreciation of                                                
 $476,884as of December 31, 2013 and              23,988             36,624 
 $458,708 as of December 31, 2012                                           
Patents, net of accumulated                                                 
 amortization of $498,502 as of                                             
 December 31, 2013 and $420,556 as of                                       
 December 31, 2012                               591,735            648,662 
Other assets                                      12,917              7,317 
                                       -----------------  ----------------- 
      Total assets                     $       8,055,346  $       5,661,103 
                                       =================  ================= 
                                                                            
 LIABILITIES AND STOCKHOLDERS' EQUITY                                       
Current Liabilities:                                                        
  Accounts payable                     $       2,020,368  $       2,336,594 
  Accrued expenses and other payable             515,132            581,407 
  Accrued interest on Notes Payable                    -            356,563 
                                       -----------------  ----------------- 
    Total current liabilities                  2,535,500          3,274,564 
                                       -----------------  ----------------- 
                                                                            
Long-term Liabilities:                                                      
  Notes payable                                        -            450,000 
                                       -----------------  ----------------- 
    Total long-term liabilities                        -            450,000 
                                       -----------------  ----------------- 
                                                                            
Commitments and Contingencies                                               
                                                                            
Stockholders' Equity                                                        
  Preferred Stock, par value $.001,                                         
   5,000,000 shares                                    -                  - 
  Common stock, par value $.001;                                            
   authorized 50,000,000 shares;                                            
   17,759,540 shares issued 1,839,930                                       
   shares to be issued and 17,726,207                                       
   shares outstanding as of December                                        
   31, 2013; 16,563,306 shares issued                                       
   1,635,709 shares to be issued and                                        
   16,529,973 shares out                          19,599             18,199 
  Additional paid-in capital                  66,677,200         64,560,224 
  Accumulated deficit                        (60,265,438)       (61,730,368)
  Treasury stock, at cost, 33,333                                           
   shares                                       (911,516)          (911,516)
                                       -----------------  ----------------- 
    Total stockholders' equity                 5,519,846          1,936,539 
                                       -----------------  ----------------- 
      Total liabilities and                                                 
       stockholders' equity            $       8,055,346  $       5,661,103 
                                       -----------------  ----------------- 
                                                                            
                                                                            
                                                                            

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
Ayehu provides IT Process Automation & Orchestration solutions for IT and Security professionals to identify and resolve critical incidents and enable rapid containment, eradication, and recovery from cyber security breaches. Ayehu provides customers greater control over IT infrastructure through automation. Ayehu solutions have been deployed by major enterprises worldwide, and currently, support thousands of IT processes across the globe. The company has offices in New York, California, and Isr...
Tintri VM-aware storage is the simplest for virtualized applications and cloud. Organizations including GE, Toyota, United Healthcare, NASA and 6 of the Fortune 15 have said "No to LUNs." With Tintri they manage only virtual machines, in a fraction of the footprint and at far lower cost than conventional storage. Tintri offers the choice of all-flash or hybrid-flash platform, converged or stand-alone structure and any hypervisor. Rather than obsess with storage, leaders focus on the business app...
Addteq is one of the top 10 Platinum Atlassian Experts who specialize in DevOps, custom and continuous integration, automation, plugin development, and consulting for midsize and global firms. Addteq firmly believes that automation is essential for successful software releases. Addteq centers its products and services around this fundamentally unique approach to delivering complete software release management solutions. With a combination of Addteq's services and our extensive list of partners,...
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform and how we integrate our thinking to solve complicated problems. In his session at 19th Cloud Expo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and sh...
Big Data, cloud, analytics, contextual information, wearable tech, sensors, mobility, and WebRTC: together, these advances have created a perfect storm of technologies that are disrupting and transforming classic communications models and ecosystems. In his session at @ThingsExpo, Erik Perotti, Senior Manager of New Ventures on Plantronics’ Innovation team, provided an overview of this technological shift, including associated business and consumer communications impacts, and opportunities it m...
WebRTC is about the data channel as much as about video and audio conferencing. However, basically all commercial WebRTC applications have been built with a focus on audio and video. The handling of “data” has been limited to text chat and file download – all other data sharing seems to end with screensharing. What is holding back a more intensive use of peer-to-peer data? In her session at @ThingsExpo, Dr Silvia Pfeiffer, WebRTC Applications Team Lead at National ICT Australia, looked at differ...
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
SYS-CON Events announced today that IoT Now has been named “Media Sponsor” of SYS-CON's 20th International Cloud Expo, which will take place on June 6–8, 2017, at the Javits Center in New York City, NY. IoT Now explores the evolving opportunities and challenges facing CSPs, and it passes on some lessons learned from those who have taken the first steps in next-gen IoT services.
The Internet of Things can drive efficiency for airlines and airports. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Sudip Majumder, senior director of development at Oracle, discussed the technical details of the connected airline baggage and related social media solutions. These IoT applications will enhance travelers' journey experience and drive efficiency for the airlines and the airports.
SYS-CON Events announced today that WineSOFT will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Based in Seoul and Irvine, WineSOFT is an innovative software house focusing on internet infrastructure solutions. The venture started as a bootstrap start-up in 2010 by focusing on making the internet faster and more powerful. WineSOFT’s knowledge is based on the expertise of TCP/IP, VPN, SSL, peer-to-peer, mob...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain.